Novozymes


H1 20: soft guidance takes centre stage

14/08/20 -"Novozymes reported largely in line Q2 20 numbers as sales were down 2% (in line with the trading update) and the EBIT margin came in at 25.9% (-10bp vs trading update). The key takeaway was the ..."

Pages
67
Language
English
Published on
14/08/20
You may also be interested by these reports :
17/09/20
Since our last Teaser in May 2019, it has been a rollercoaster ride for Grifols (Buy, Spain), a leading player in the $23bn oligopolistic plasma ...

17/09/20
Merck confirmed our positive view on the company. As expected, management confirmed the FY 2022 guidance and put some nice colour on 2021. The ...

09/09/20
In line with its strategy of expanding its focus on the immuno-oncology space and strengthening its internal R&D pipeline, Sanofi has spent €5.2bn on ...

07/09/20
Surprisingly, Akebia’s oral HIF-PHI drug, Vadadustat, has shown heart safety concerns in a phase III study for non-dialysis CKD-anaemic patients. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO